Click to view your profile
Click to search for condition or expert
Click to open main menu
Non-Small Cell Lung Cancer (NSCLC) Latest Advances
Find the Latest Research About Non-Small Cell Lung Cancer (NSCLC)
Save
Bookmark
Share
Share
Overview
Find a Doctor
Latest Advances
Clinical Trials
Treatments
Customize your search results with filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 02/19/2023
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1878 publications
See more filters
Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer.
Condition:
Triple-Negative/Her2( +) Breast Cancer, Multiple Myeloma, and Non-Small-Cell Lung Cancer
Journal:
Journal of the Egyptian National Cancer Institute
Treatment Used:
Combination Immunotherapy and Chemotherapy
Number of Patients:
0
Published:
January 01, 2023
VIEW PUBLICATION
Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy.
Condition:
Non-Small Cell Lung Cancer (NSCLC)
Journal:
Frontiers in immunology
Treatment Used:
Sintilimab Plus Autologous NK Cells
Number of Patients:
20
Published:
December 26, 2022
VIEW PUBLICATION
Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.
Condition:
Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Journal:
Frontiers in immunology
Treatment Used:
Combining Programmed Cell Death (PD-1) or Programmed Cell Death Ligand 1 (PD-L1) Inhibitors with Chemotherapy vs. Chemotherapy Alone
Number of Patients:
2600
Published:
December 22, 2022
VIEW PUBLICATION
Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
Condition:
Stage III Lung Squamous Cell Carcinoma (SCC)
Journal:
Drug design, development and therapy
Treatment Used:
PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin
Number of Patients:
14
Published:
December 21, 2022
VIEW PUBLICATION
Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.
Condition:
Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Nonsmall Cell Lung Cancer (NSCLC)
Journal:
Medicine
Treatment Used:
Icotinib
Number of Patients:
957
Published:
December 09, 2022
VIEW PUBLICATION
Reconstruction of post-resection chest wall defects in surgical treatment of invasive non-small cell lung cancer.
Condition:
Invasive Non-Small Cell Lung Cancer (NSCLC)
Journal:
Khirurgiia
Treatment Used:
Reconstruction of Post-Resection Chest Wall Defects with Nickel-Titanium (TiNi) Implants
Number of Patients:
9
Published:
December 05, 2022
VIEW PUBLICATION
Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Condition:
EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal:
Pharmacology
Treatment Used:
Osimertinib
Number of Patients:
1848
Published:
December 05, 2022
VIEW PUBLICATION
A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer.
Condition:
Epidermal Growth Factor Receptor (EGFR) Mutation of Resected Non-Small Cell Lung Cancer (NSCLC)
Journal:
Medicine
Treatment Used:
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) vs. Adjuvant Chemotherapy (ACT)
Number of Patients:
1694
Published:
December 01, 2022
VIEW PUBLICATION
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Condition:
Non-Small Cell Lung Cancer (NSCLC)
Journal:
Thoracic cancer
Treatment Used:
Afatinib
Number of Patients:
230
Published:
November 25, 2022
VIEW PUBLICATION
EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review.
Condition:
Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC)
Journal:
Medicina (Kaunas, Lithuania)
Treatment Used:
EGFR Tyrosine Kinase Inhibitor (TKI)
Number of Patients:
1327
Published:
November 24, 2022
VIEW PUBLICATION
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
Condition:
Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal:
Cancer
Treatment Used:
Chemotherapy Plus Pembrolizumab
Number of Patients:
35
Published:
November 24, 2022
VIEW PUBLICATION
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
Condition:
Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Journal:
Lung cancer (Amsterdam, Netherlands)
Treatment Used:
Lorlatinib vs. Crizotinib
Number of Patients:
288
Published:
November 21, 2022
VIEW PUBLICATION
Showing 1-12 of 1,878
Next
Last Updated: 02/19/2023